In this week’s edition of InnovationRx, Medline’s blockbuster IPO, Fred Moll’s surgical robotics investments, Forbes’ inaugural top hospitals list, and more. To get it in your inbox, subscribe here.Charlie Mills, Medline’s former CEO and a key member of its founding familyAFP via Getty ImagesMedical supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 19 ...

Core Insights - The Mills family, founders of Medline, sold a majority stake to private equity in 2021 for $30 billion, but their remaining stake is now valued at $6 billion to $7 billion, contributing to a total estimated net worth of $20 billion for the family [1][2][3] - Medline is preparing for a significant IPO this winter, potentially valued at up to $55 billion, marking it as a major event in the market [1] - The company's sales have surged to $25.5 billion in 2024, an 83% increase from $13.9 billion five years prior, with profits rebounding to $1.2 billion [8] Company Background - Medline was founded in 1910 by A.L. Mills, initially selling butcher's aprons before transitioning to medical supplies after a request from a local hospital seamstress [5] - The company has a history of innovation, including the introduction of the first surgeon's gown with 360-degree coverage and the commercialization of specific fabrics to reduce glare in operating rooms [5] Recent Developments - The Mills family established a family office called Council Ring Capital after the 2021 sale and began stepping back from day-to-day operations in 2023 [3][7] - Jim Boyle became the first non-family CEO of Medline in October 2023, indicating a shift in leadership dynamics [7] - Medline's role in the pandemic response was significant, distributing medical supplies to nursing homes, pharmacies, and 45% of hospital systems nationwide [6]

Private equity-backed Medline is aiming to raise as much as $5.37 billion in its initial public offering in the United States, the medical supplies provider said on Monday. ...

Brown Advisory, an investment management company, released its “Brown Advisory Large-Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned -0.88% (net) during the third quarter, underperforming the benchmark, the Russell 1000 Growth Index. Even though the portfolio has significant exposure to AI, its underweight to the most speculative momentum-driven parts of the trade was a headwind to performance. In addition, please check the fund’s t ...

MELBOURNE, Australia and PALM BEACH, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CYIOS Corp. (OTC: CYIO), a diversified holding company focused on acquiring, building, and scaling high-growth businesses in the medical, technology, and innovation sectors, is pleased to announce the appointment of John O’Shea as its new Chief Executive Officer and Chairman of the Board. A serial entrepreneur, published author, and seasoned senior executive with more than 30 years of experience across finance, technology, educatio ...

AdaptHealth Corp. to Participate in Upcoming Investor Conference Share CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) ("AdaptHealth†or the "Company†), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the BofA Securities Leveraged Finance Conference, being held in Boca Raton, FL, on Tuesday, December 2, 2025, including a fireside chat at ...

Financial Data and Key Metrics Changes - For Q4 2025, Embecta generated $264 million in revenue, reflecting a 7.7% decline year-over-year on an as-reported basis or a 10.4% decline on an adjusted cost and currency basis [10] - GAAP gross profit for Q4 2025 totaled $158.5 million with a margin of 60%, compared to $173.8 million and 60.7% in the prior year [15] - Adjusted net income for Q4 2025 was $29.4 million, or $0.50 per diluted share, compared to $25.9 million and $0.45 in the prior year [17] Business Line Data and Key Metrics Changes - In Q4 2025, pen needle revenue declined approximately 13.9%, while syringe revenue declined by approximately 4.5% [12] - Safety products grew approximately 3.7%, and contract manufacturing revenue grew approximately 8.5% during the same period [12] - For the full year, pen needle revenue declined approximately 7.1%, while syringe revenues grew by 1.7% and safety products grew by 6.3% [14] Market Data and Key Metrics Changes - U.S. revenue for Q4 totaled $142 million, reflecting a year-over-year decline of 15.2% on an adjusted cost and currency basis [11] - International revenue for Q4 totaled $122 million, representing an increase of 2.8% on a reported basis but a decline of 4% on an adjusted cost and currency basis, primarily due to lower volumes in China [12] - The decline in international revenue was primarily due to lower revenue contribution from China, driven by heightened competitive intensity and local brand preferences [14] Company Strategy and Development Direction - The company ended its patch pump program and executed a restructuring plan aimed at enhancing profitability and free cash flow [5] - Embecta is collaborating with over 30 pharmaceutical partners to co-package pen needles with generic GLP-1 therapies, anticipating launches in Canada, Brazil, and India during calendar year 2026 [7] - The company aims to maintain its leadership position in core product categories while expanding into new market segments through product development programs [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made during fiscal 2025 and outlined a strategic direction for sustainable growth [10] - The company anticipates a flat to down 2% revenue change for fiscal 2026, with expectations of modest declines in core injection and contract manufacturing revenue [22] - Management acknowledged the challenges posed by geopolitical tensions, particularly in China, but remains optimistic about long-term market potential [40] Other Important Information - Embecta generated approximately $182 million in free cash flow during fiscal 2025 and repaid approximately $184 million of debt [21] - The company expects to generate between $180 million and $200 million in free cash flow during fiscal 2026 [29] - A transaction to sell certain intellectual property rights associated with the discontinued patch pump program for $10 million occurred after year-end [21] Q&A Session Summary Question: Details on GLP-1 partnerships - Management is in discussions with over 30 potential GLP-1 entrants, with several already providing orders for development purposes [33][34] Question: Consumer willingness to buy non-Chinese products in China - Management noted that Q4 2025 performance in China met expectations, and steps have been taken to stabilize the situation [39][40] Question: Increased cannula costs and sourcing alternative suppliers - The company is working on identifying alternate cannula suppliers to mitigate cost increases and reduce reliance on a sole source [45][46] Question: Clarification on milestone payments to a U.S. pharmacy customer - Management explained that milestone payments are related to volume levels and marketing spend, impacting pricing dynamics [49] Question: Structure of contracts with generic GLP-1 providers - Management discussed the initial phases of contracting and the importance of reliability in supply for generic manufacturers [56][58] Question: Capital deployment and M&A opportunities - Management remains focused on debt repayment but is open to organic and inorganic investments as leverage decreases [64][65] Question: Sale of intellectual property associated with the patch pump - The sale of certain IP for $10 million will increase cash but will not impact adjusted results for fiscal 2026 [70]

Financial Data and Key Metrics Changes - For fiscal year 2025, the company generated adjusted revenues of approximately $1.08 billion, reflecting a decline of 3.9% on an adjusted cost and currency basis [13] - The fourth quarter revenue was $264 million, a 7.7% decline year-over-year on an as-reported basis, or a 10.4% decline on an adjusted cost and currency basis [10] - GAAP net income for fiscal 2025 was $95.4 million, compared to $78.3 million in the prior year, while adjusted net income was $173.9 million, up from $143.1 million [21][22] Business Line Data and Key Metrics Changes - Pen needle revenue declined approximately 7.1% year-over-year, totaling $784.1 million, primarily due to advanced distributor ordering in the prior year and pricing headwinds [14] - Syringe product revenues grew by 1.7% year-over-year, driven by improved pricing, while safety products grew 6.3% due to a combination of improved pricing and volume increases [15] - Contract manufacturing revenue grew approximately 53.9% compared to the prior year [15] Market Data and Key Metrics Changes - U.S. revenue for the fourth quarter totaled $142 million, reflecting a year-over-year decline of 15.2% on an adjusted cost and currency basis [11] - International revenue for the fourth quarter was $122 million, representing an increase of 2.8% on a reported basis but a decline of 4% on an adjusted cost and currency basis, primarily due to lower volumes and pricing headwinds in China [12] - The decline in international revenue was largely attributed to lower revenue contribution from China, driven by heightened competitive intensity and local brand preferences [14] Company Strategy and Development Direction - The company ended its patch pump program and executed a restructuring plan aimed at enhancing profitability and free cash flow [5] - The company is advancing its GLP-1 strategy, collaborating with over 30 pharmaceutical partners to co-package pen needles with generic GLP-1 therapies, anticipating a $100 million annual revenue opportunity by 2033 [6][8] - The company aims to maintain leadership in core product categories while expanding its portfolio through new product development programs [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's direction despite a complex geopolitical and trade backdrop, focusing on maintaining leadership in core categories and delivering strong profitability and cash flow [58][59] - The company anticipates flat to down 2% revenue growth on an adjusted constant currency basis for fiscal year 2026, with expectations of modest declines in core injection and contract manufacturing revenue [25][26] - Management highlighted the importance of stabilizing the situation in China and remains optimistic about long-term growth in that market [39] Other Important Information - The company generated approximately $182 million in free cash flow during fiscal year 2025 and repaid approximately $184 million of debt, ending the year with a net leverage level of approximately 2.9 times [23] - The company sold certain intellectual property rights and long-lived assets associated with the discontinued patch pump program for $10 million, which will not impact adjusted results for fiscal year 2026 [54] Q&A Session Summary Question: Details on GLP-1 partnerships - The company is in discussions with over 30 potential GLP-1 entrants, with several already providing orders and submitting regulatory submissions [33][34] Question: Consumer willingness to buy non-Chinese products in China - The company has taken steps to stabilize the situation in China and introduced a more price-competitive pen needle [38] Question: Increased cannula costs and sourcing alternative suppliers - The company is working on identifying alternate cannula suppliers to mitigate cost increases and has made significant progress [41][43] Question: Milestone payments to a large U.S. pharmacy customer - Milestone payments are related to contract terms that include rebates and marketing spend, which can lead to year-over-year price fluctuations [44] Question: Capital deployment and M&A opportunities - The company remains focused on paying down debt but is open to organic and inorganic investments if value-creative opportunities arise [52]

Core Insights - Exact Sciences Corp. is reinforcing its leadership in breast cancer diagnostics with a strong presence at the 2025 San Antonio Breast Cancer Symposium, presenting 10 abstracts from its Precision Oncology portfolio [1][2][3] Group 1: Oncodetect Test - The Oncodetect test will be clinically validated for triple-negative breast cancer (TNBC), showcasing its high sensitivity in detecting molecular residual disease (MRD) [1][4] - A sub-study in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP) demonstrated the strong predictive performance of the Oncodetect test in patients with early TNBC undergoing neoadjuvant chemotherapy [4][6] Group 2: Oncotype DX Test - The Oncotype DX test is recognized as a global standard for predicting and prognosing breast cancer, aiding clinicians in therapy decisions that improve outcomes and reduce disparities [3][7] - A study confirmed that the Oncotype DX Breast Recurrence Score test can lead to improved outcomes and reduced costs across diverse racial and ethnic subgroups in the US, promoting equitable breast cancer care [7][8] Group 3: Real-World Data and Economic Impact - Real-world data analysis indicates an increasing trend in the adoption of molecular residual disease testing in breast cancer, highlighting its integration into clinical practice [6][8] - The use of the Oncotype DX test in Ireland has resulted in estimated cost savings of over 60 million euros associated with chemotherapy use over an 11-year period [11] Group 4: International Studies - A large-scale study in Japan confirmed appropriate application of the Oncotype DX test in HR+/HER2 early breast cancer, consistent with current guidelines [9] - A prospective evaluation in Switzerland found that the Oncotype DX test significantly influenced adjuvant treatment decisions, particularly in driving chemotherapy de-escalation [10]

Core Insights - Butterfly Network, Inc. is participating in the 8th Annual Evercore Healthcare Conference, with key executives scheduled for a fireside chat and one-on-one investor meetings [1][2] - The company is recognized for its innovative Ultrasound-on-Chip™ technology and has launched several handheld ultrasound systems, including the award-winning iQ3 [3][4] Company Overview - Butterfly Network, Inc. is a digital health company focused on transforming medical imaging through handheld, whole-body ultrasound technology and intuitive software solutions [1][3] - The company launched the first handheld, single-probe, whole-body ultrasound system, Butterfly iQ, in 2018, followed by the iQ+ in 2020 and the iQ3 in 2024, each improving in processing power and performance [3] - The iQ3 received the Best Medical Technology award at the 2024 Prix Galien USA Awards, highlighting its significance in the healthcare sector [3] Product and Technology - Butterfly combines advanced hardware, intelligent software, AI, services, and education to enhance the adoption of affordable and accessible imaging solutions [4] - The company’s handheld ultrasound probes, paired with Compass™ enterprise workflow software, have been shown to improve care workflows, reduce costs, and enhance provider economics [4] - Butterfly's devices are available to trained healthcare practitioners globally, addressing critical healthcare challenges [4]